Mevion Medical Systems, a leader in compact proton therapy solutions, has announced that its MEVION S250i Proton Therapy System has received approval from the National Medical Products Administration (NMPA) of China. This approval marks a significant milestone, making Mevion the first company to offer an integrated, compact proton therapy system to cancer patients in China.
Mevion Medical Systems has announced that its MEVION S250i Proton Therapy System has received approval from the National Medical Products Administration (NMPA) of China. This makes the MEVION S250i the first compact, integrated proton therapy system approved in China. The system’s approval marks a significant advancement in providing cutting-edge cancer treatment to patients in China.
The MEVION S250i is the first compact, integrated single-room proton therapy system to receive clearance in the USA and now China. Its innovative design combines a superconducting proton accelerator with an integrated gantry, offering a smaller footprint and reduced energy consumption compared to traditional proton therapy systems. The system also incorporates HYPERSCAN pencil beam scanning technology, which enables faster, more precise tumor targeting. Additionally, the Adaptive Aperture pMLC technology minimizes damage to healthy tissue, potentially reducing side effects for patients.
“We are thrilled to receive NMPA approval for the MEVION S250i,” said Dr. Tina Yu, CEO of Mevion Medical Systems. “This approval reflects our commitment to providing innovative and accessible cancer treatment solutions, and we believe the advancement of the MEVION S250i will significantly contribute to the fight against cancer in China.”
The MEVION S250i offers multiple advantages over conventional proton therapy systems, including:
- Compact Size: Its smaller footprint makes it easier to integrate into existing hospitals and clinics, allowing facilities to offer proton therapy without the need for extensive infrastructure changes.
- Cost-Effectiveness: The MEVION S250i is more affordable than traditional proton therapy systems, increasing accessibility for a wider range of patients.
- Faster Treatment Times: The HYPERSCAN technology accelerates treatment, improving patient comfort and convenience by reducing the time spent in treatment.
- Enhanced Precision: Adaptive Aperture pMLC ensures accurate dose delivery to tumors while minimizing harm to surrounding healthy tissue, reducing potential side effects.
Mevion is dedicated to expanding access to proton therapy in China, offering comprehensive services such as training, education, and ongoing maintenance to support customers. This expansion builds upon Mevion’s strong success in the USA, where the company is the market leader in compact proton therapy, with over 50% of clinical compact centers utilizing Mevion technology. The company has a strong presence in NCI Comprehensive Cancer Centers, highlighting its leadership in clinical innovation, financial viability, and cutting-edge research in proton therapy.
About Mevion Medical Systems
Mevion Medical Systems is the leading provider of compact proton therapy systems for cancer treatment. Known for pioneering the single-room platform, Mevion continues to advance proton therapy technology. Since 2013, its systems have been used in top cancer centers worldwide. With the MEVION S250i and MEVION S250-FIT featuring HYPERSCAN, Mevion leads the way in providing compact, cost-effective proton therapy solutions. Headquartered in Littleton, Massachusetts, Mevion operates globally, including in Europe and Asia.
